Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2013Leukemia & lymphoma/Leukemia and lymphoma

Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval

View Full Paper
Ask AI
Bookmark
Share

Authors

HGHolly Lynn GeyerKCKeith CannonEKEmily Knight

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Geyer et al. (2013) studied this question.

synapsesocial.com/papers/6ab49d29fbdb072f4eeb79dahttps://doi.org/10.3109/10428194.2013.789507
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Biology and Treatment of Primary Myelofibrosis2007 · 49 citations
  2. 2The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients2011 · 335 citations
  3. 3A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis2012 · 2,108 citations
  4. 4The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)2006 · 402 citations
  5. 5Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases2004 · 390 citations